First American Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

First American Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-430	Closed	-$214K	–	322
2026 Q2	$214K	Sell	430 -28	-6%	-$12.4K	0.01%	281
2026 Q1	$205K	Sell	458 -2,019	-82%	-$941K	0.01%	269
2025 Q4	$1.12M	Sell	2,477 -484	-16%	-$209K	0.08%	146
2025 Q3	$1.16M	Sell	2,961 -8,387	-74%	-$3.51M	0.08%	135
2025 Q2	$5.05M	Sell	11,348 -5,663	-33%	-$2.61M	0.4%	78
2025 Q1	$8.25M	Buy	17,011 +514	+3%	+$240K	0.76%	40
2024 Q4	$6.64M	Sell	16,497 -20	-0.1%	-$9.27K	0.66%	52
2024 Q3	$7.68M	Sell	16,517 -2,275	-12%	-$1.09M	0.76%	45
2024 Q2	$8.81M	Buy	18,792 +971	+5%	+$421K	0.88%	38
2024 Q1	$7.45M	Buy	17,821 +521	+3%	+$220K	0.78%	42
2023 Q4	$7.04M	Sell	17,300 -5,689	-25%	-$2.1M	0.87%	43
2023 Q3	$7.99M	Sell	22,989 -529	-2%	-$185K	1.13%	31
2023 Q2	$8.28M	Buy	23,518 +805	+4%	+$271K	1.14%	26
2023 Q1	$7.16M	Buy	22,713 +1,022	+5%	+$307K	1.06%	34
2022 Q4	$6.26M	Buy	21,691 +860	+4%	+$262K	0.97%	40
2022 Q3	$6.03M	Buy	20,831 +858	+4%	+$247K	1.01%	36
2022 Q2	$5.63M	Buy	+19,973	New	+$5.35M	0.89%	46

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

First American Trust's VRTX Position: Q3 2026 in Review

First American Trust sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 430 shares — an estimated $214K sold.

First American Trust first reported a position in VRTX in Q2 2022 and held it in 17 quarters. The position peaked at $8.81M in Q2 2024. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

First American Trust reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
First American Trust sold 430 Vertex Pharmaceuticals shares in Q3 2026, an estimated $214K.
First American Trust first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 17 quarters.
First American Trust's Vertex Pharmaceuticals position peaked at $8.81M in Q2 2024.
1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on First American Trust's 13F filing for Q3 2026, filed 12 Nov 2026.